Cargando…

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed

Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denton, Christopher P, Avouac, Jerome, Behrens, Frank, Furst, Daniel E, Foeldvari, Ivan, Humbert, Marc, Huscher, Doerte, Kowal-Bielecka, Otylia, Matucci-Cerinic, Marco, Nash, Peter, Opitz, Christian F, Pittrow, David, Rubin, Lewis J, Seibold, James R, Distler, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218892/ https://www.ncbi.nlm.nih.gov/pubmed/21699746 http://dx.doi.org/10.1186/ar3346

Ejemplares similares

High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis
por: Kowal-Bielecka, Otylia, et al.
Publicado: (2013)

Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables
por: Pausch, Christine, et al.
Publicado: (2023)

Regulation of eicosanoid production in peripheral blood mononuclear cells from patients with systemic sclerosis
por: Kowal-Bielecka, Otylia, et al.
Publicado: (2007)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Clinical trials in systemic sclerosis: lessons learned and outcomes
por: Matucci-Cerinic, Marco, et al.
Publicado: (2007)

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
por: Dobrota, Rucsandra, et al.
Publicado: (2016)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
por: Taylor, Peter C., et al.
Publicado: (2022)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Comparison of hyaluronic acid in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus
por: Cylwik, Bogdan, et al.
Publicado: (2021)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Diagnostic Power of Galectin-3 in Rheumatic Diseases
por: Gruszewska, Ewa, et al.
Publicado: (2020)

Expression of LIGHT/TNFSF14 and Its Receptors, HVEM and LTβR, Correlates with the Severity of Fibrosis in Lacrimal Sacs from Patients with Lacrimal Duct Obstruction
por: Bielecki, Pawel, et al.
Publicado: (2020)

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
por: Schmidt, Kai-Helge, et al.
Publicado: (2023)

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
por: Hoeper, Marius M., et al.
Publicado: (2015)

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
por: Blagojevic, J., et al.
Publicado: (2019)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Could IL-1β, IL-6, IFN-γ, and sP-selectin serum levels be considered as objective and quantifiable markers of rheumatoid arthritis severity and activity?
por: Koper-Lenkiewicz, Olga M., et al.
Publicado: (2022)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Purtscher-like Retinopathy in a Patient with Systemic Sclerosis: A Case Report and Narrative Review
por: Pieklarz, Barbara, et al.
Publicado: (2023)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

Type B insulin resistance syndrome associated with connective tissue disease and psoriasis
por: Łebkowska, Agnieszka, et al.
Publicado: (2020)

Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review
por: Wang, YuKai, et al.
Publicado: (2017)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Subclinical Cardiovascular System Changes in Obese Patients with Juvenile Idiopathic Arthritis
por: Głowińska-Olszewska, Barbara, et al.
Publicado: (2013)

Peripapillary choroidal vascularity index and thickness in patients with systemic sclerosis
por: Pieklarz, Barbara, et al.
Publicado: (2023)

Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease
por: Rubin, Lewis J, et al.
Publicado: (2007)

Systemic sclerosis and related connective tissue diseases: present and future
por: Rubin, Lewis J, et al.
Publicado: (2007)

Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis
por: Allanore, Yannick, et al.
Publicado: (2011)

Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2013)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany
por: Kramm, Thorsten, et al.
Publicado: (2018)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort
por: Allanore, Yannick, et al.
Publicado: (2016)

Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry
por: Matucci-Cerinic, Marco, et al.
Publicado: (2016)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

P1611: INSIGHTS INTO FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: FINAL RESULTS FROM THE FIGARO STUDY
por: Dimou, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c15t6ls3q4a8mepuubuneiis01